ABSTRACT
To determine the prevalence and risk factor of anti-HCV in ESRD patients under chronic maitenance hemodialysis, the prevalence of serum antibodies to hepatitis C Virus(Anti-HCV) was assessed by an enzyme immunoassay (Abbott HCV EIA) in 253 patients with long-term Hemodialysis in Daegu & Kyoungbuk. 15 patients(5.9%) were anti-HCV positive. All dialysis patients had the history of transfusion. The number of transfusion units was not significant in anti-HCV positive patients(mean 17+/-20 pints) in comparison with the number in anti-HCV negative patients (mean 16+/-17 pints). The frequency of hemodialysis was also not significant in anti-HCV positive patients(mean 477+/-618 ) compared with anti-HCV negative patients (mean 462+/-616). The mean duration of hemodialysis was significantly higher(P<0.001) in the anti-HCV positive patients (74+/-42 months) in comparison with anti-HCV negative patients (45+/-41 months). We concluded that the prevalence of anti-HCV in hemodialysis patients is 5.9% and that HCV infection is significantly related with the duration of hemodialysis rather than the number of transfusion units and the frequency of hemodialysis
Subject(s)
Humans , Antibodies , Dialysis , Hepacivirus , Hepatitis C , Immunoenzyme Techniques , Kidney Failure, Chronic , Korea , Prevalence , Renal Dialysis , Risk FactorsABSTRACT
Thymoma has been associated with a variety of diseases, including myasthenia gravis, pure red cell aplasia (PRCA), hypogammaglobulinemia, and other abnormal immune and endocrine disorders. Herein we report a case of PRCA associated with invasive thymoma in a 65-year-old man. In spite of total thymectomy and irradiation to the mediastinum, no significant response was observed. The mechanisms and management of PRCA associated with invasive thymoma are reviewed.